TY - JOUR
T1 - The importance of para-aortic lymph nodes in sentinel lymph node mapping for endometrial cancer by using hysteroscopic radio-isotope tracer injection combined with subserosal dye injection
T2 - Prospective study
AU - Kataoka, Fumio
AU - Susumu, Nobuyuki
AU - Yamagami, Wataru
AU - Kuwahata, Michiko
AU - Takigawa, Aya
AU - Nomura, Hiroyuki
AU - Takeuchi, Hiroya
AU - Nakahara, Tadaki
AU - Kameyama, Kaori
AU - Aoki, Daisuke
N1 - Funding Information:
The authors are grateful to Ms. Tomomi Noda and Ms. Keiko Abe of Keio University School of Medicine for their secretarial help. This work was supported in part by the Keio Gijuku Academic Development Funds .
Publisher Copyright:
© 2016 Elsevier Inc. All rights reserved.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Objective The objective of this study is to evaluate the detection rate and diagnostic accuracy of sentinel lymph node (SN) mapping using hysteroscopic sub-endometrial injection of 99m-Technetium labeled phytate (Radio-isotope; RI method) and subserosal Indocyanine green (ICG) injection (Dye method) in patients with endometrial cancer. Methods From April 2009 to December 2012, prospective evaluation of 57 Japanese endometrial cancer patients undergoing SN mapping using RI method combined with Dye method was done. To combine RI method or no was determined by a status of RI supply of the tracer injection day. As for 32 cases, both (RI + Dye) methods were used and 23 cases were performed only in Dye method. The primary endpoint was estimation of sensitivity and negative predictive value (NPV) of SN, and analysis of the distribution of SNs with metastasis. Results At least one SN was detected in 100% and average number of detected SNs was 6.0 in RI + Dye method. Sensitivity and NPV were 100%, 100%, respectively. From results of SN mapping, 62.8% of SNs were present in pelvic and 37.1% in para-aortic lymph nodes (PAN). Total 56.3% of lymph nodes with metastasis were present in pelvic and 43.8% in PAN, and the distribution has no difference with SN mapping results (P = 0.602). Among 13 cases with metastatic SNs, 76.9% cases showed metastasis in PAN. Conclusions This SN mapping procedure for endometrial cancer patients revealed high detection rate, sensitivity, NPV, and also indicated the importance of the SN exploration in PAN area.
AB - Objective The objective of this study is to evaluate the detection rate and diagnostic accuracy of sentinel lymph node (SN) mapping using hysteroscopic sub-endometrial injection of 99m-Technetium labeled phytate (Radio-isotope; RI method) and subserosal Indocyanine green (ICG) injection (Dye method) in patients with endometrial cancer. Methods From April 2009 to December 2012, prospective evaluation of 57 Japanese endometrial cancer patients undergoing SN mapping using RI method combined with Dye method was done. To combine RI method or no was determined by a status of RI supply of the tracer injection day. As for 32 cases, both (RI + Dye) methods were used and 23 cases were performed only in Dye method. The primary endpoint was estimation of sensitivity and negative predictive value (NPV) of SN, and analysis of the distribution of SNs with metastasis. Results At least one SN was detected in 100% and average number of detected SNs was 6.0 in RI + Dye method. Sensitivity and NPV were 100%, 100%, respectively. From results of SN mapping, 62.8% of SNs were present in pelvic and 37.1% in para-aortic lymph nodes (PAN). Total 56.3% of lymph nodes with metastasis were present in pelvic and 43.8% in PAN, and the distribution has no difference with SN mapping results (P = 0.602). Among 13 cases with metastatic SNs, 76.9% cases showed metastasis in PAN. Conclusions This SN mapping procedure for endometrial cancer patients revealed high detection rate, sensitivity, NPV, and also indicated the importance of the SN exploration in PAN area.
KW - Endometrial cancer
KW - Hysteroscopic
KW - Para-aortic lymph node
KW - Sentinel lymph node
UR - http://www.scopus.com/inward/record.url?scp=84959267642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959267642&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2015.12.023
DO - 10.1016/j.ygyno.2015.12.023
M3 - Article
C2 - 26731727
AN - SCOPUS:84959267642
SN - 0090-8258
VL - 140
SP - 400
EP - 404
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -